Records are supplied by study sponsors and investigators. A registry listing is not an endorsement or a guarantee of safety, availability or eligibility.
WCR feed checked: Nov 12, 2026.
RecruitingNCT06515613
Platinum-resistant Ovarian Cancer · Testicular Cancer · Endometrial Cancer
Phase 118 years - Not specifiedLittle Rock, Arkansas, United States +14 This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with platinum-refractory/resistant ovarian canc…
CompletedNCT02363335
Healthy Volunteers
Phase 121 years - 55 yearsBaltimore, Maryland, United States Background: The drug Roflumilast (Daliresp) is used to treat Chronic Obstructive Pulmonary Disease (COPD). COPD is a lung disease that makes it difficult to breathe. Studies have shown that this drug decreased the blood sugar of people with type 2 di…
Active, not recruitingNCT06565455
Pediatric Obesity · Health Behavior, Risky
Not applicable7 years - Not specifiedLittle Rock, Arkansas, United States Childhood obesity is a national problem with racial and ethnic disparities specifically among Hispanic children. The primary purpose of this study is to develop and implement a culturally appropriate healthy eating intervention called Growing Healthy…
RecruitingNCT06730126
Autoimmune Lymphoproliferative Syndrome
Phase 216 years - 120 yearsBethesda, Maryland, United States +2 Background: Autoimmune lymphoproliferative syndrome (ALPS) is a rare disorder of the immune system caused by a mutation in the FAS gene. In ALPS, the body stores too many germ-fighting cells called lymphocytes. This can lead to an enlarged spleen and…
Not yet recruitingNCT07927491
Recurrent Glioblastoma With EGFR Mutation
Phase 118 years - Not specifiedBoston, Massachusetts, United States +2 This is an open-label, first-in-human phase 1 and surgical window of opportunity study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of CM93 in subjects with recurrent glioblasto…
WithheldNCT07930052
Not reportedNot specified - Not specifiedLocation not listed RecruitingNCT07555938
Multiple Myeloma
Phase 318 years - Not specifiedDuarte, California, United States +93 The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior li…
CompletedNCT07439185
Gut -Microbiota · Inflamation · Iron Absorption
Not applicable9 years - 13 yearsAntsirabe, Vakinankaratra Region, Madagascar The purpose of this study is to determine the health impacts of consistent consumption of insect-fortified crackers among school-aged children in Madagascar. Specifically, in this RCT, the investigators will assess whether the insect-fortified cracke…
Active, not recruitingNCT02584244
Colorectal Cancer · Pancreatic Cancer · Esophageal Cancer · Gastric Cancer
Phase 1 / Phase 218 years - Not specifiedBoston, Massachusetts, United States The overall goal of this feasibility study is to assess the initial safety and efficacy of LUM015 in ex vivo far-red imaging of colorectal, pancreatic, and esophageal cancers (adenocarcinoma) using the LUM Imaging System.
CompletedNCT05726136
Colorectal Cancer · Urologic Cancer · Gynecologic Cancer · Colorectal Disorders · Benign Neoplasm
Phase 418 years - 85 yearsNorrköping, Östergötland County, Sweden A short bolus infusion of fluid, called "fluid challenge" is commonly recommended for fluid treatment during longer surgery. However a prolonged increase of the blood volume is a prerequisite to recommend the technique. The purpose with the study is …
RecruitingNCT07540221
CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
Phase 318 years - Not specifiedRancho Mirage, California, United States +14 The main goal of the study is to find out whether XEMBIFY, given once a week under the skin, provides similar levels of immunoglobulin G in the blood over time as Gamunex-C, which is given into a vein once every 3 weeks in people with CIDP. Participa…
RecruitingNCT06219863
Down Syndrome
Not applicableNot specified - 2 yearsBoston, Massachusetts, United States The emergence of crawling and walking is significantly delayed in infants with Down syndrome (DS), but the development of independent mobility provides infants with new opportunities for exploring the environment and interacting with objects and peop…
Retrieved from ClinicalTrials.gov: Nov 12, 2026. Overall study status may differ from a particular location’s status.
